Almac Adds Contained Drug Handling and Bottling Capabilities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Almac Adds Contained Drug Handling and Bottling Capabilities
Almac introduces handling and bottling capabilities in EU and US headquarters.



Almac announced that it has expanded its service offering for dispensing and bottling solid dosage products by introducing enhanced containment equipment and processes at its EU and US clinical services sites. The facilities are now in operation following successful installation and validation.

Dr Robert Dunlop, managing director of Almac clinical services said in a press release that there has been an increase in demand for facilities equipped to handle compounds of a higher potency in the drug-development industry and Almac has responded by expanding its service offering to address this need.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here